MNOV | tickerfilter.com

Fundamental analysis

13%

Profitability 0%

Dept financing 2%

Liquidity 50%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-8.02%

1 Month

-2.99%

3 Months

2.09%

6 Months

35.42%

1 Year

34.48%

2 Year

-3.47%

Key data

Stock price

$1.96

P/E Ratio

0.00

DAY RANGE

$1.95 - $1.97

EPS

$0.00

52 WEEK RANGE

$1.14 - $2.55

52 WEEK CHANGE

$30.00

MARKET CAP

73.569 M

YIELD

N/A

SHARES OUTSTANDING

49.046 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

0.72

PUBLIC FLOAT

AVERAGE 10 VOLUME

$51,887

AVERAGE 30 VOLUME

$56,246

Company detail

CEO: Yuichi Iwaki
Region: US
Website: medicinova.com
Employees: 10
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

MediciNova, Inc. focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders. MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the. treatment of acute exacerbations of asthma, MN-001 (tipelukast) is an orally bioavailable small molecule compound to treat fibrotic diseases.

MNOV - MEDICINOVA INC